The median PFS was 6.5 months (95 % CI, 3.9–9.3) as determined by an independent radiology review committee. The median OS was 13.5 months (95 % CI, 9.8–28.1) and the overall survival rate at 12 months was 52.6 % (95 % CI 28.7–71.9)….Our results indicated that vandetanib enabled a prolonged and clinically meaningful PFS and OS in patients with previously treated RET-rearranged advanced NSCLC at the updated final analysis.

In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily...In the intention-to-treat population of all 19 patients treated with vandetanib, nine (47% [95% CI 24-71]) achieved an objective response. At the data cutoff, median progression-free survival was 4·7 months (95% CI 2·8-8·5).

Among the 17 evaluable patients, three had a partial response (objective response rate = 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months....Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.